A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis — EoDyssey

Eosinophilic Gastroenteritis Clinical Trial

Official title:
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AK002 in Patients With Moderately to Severely Active Eosinophilic Duodenitis Who Have an Inadequate Response With, Lost Response to, or Were Intolerant to Standard Therapies

Status Completed

Clinical Trial Summary

This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002) given monthly for 6 doses in adult patients with active eosinophilic duodenitis. Subjects who complete the randomized, double-blind, placebo-controlled treatment may have the option to receive 6 doses of open-label lirentelimab (AK002) through the OLE Period of the study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04856891
Study type	Interventional
Source	Allakos Inc.
Contact
Status	Completed
Phase	Phase 3
Start date	May 20, 2021
Completion date	January 9, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03320369` - Effect of Elemental Diet on Adult Patients With Eosinophilic Gastroenteritis	N/A
Completed	`NCT00148603` - Montelukast in the Treatment of Duodenal Eosinophilia	N/A
Completed	`NCT03664960` - An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis	Phase 2
Completed	`NCT00267475` - Data Bank for Eosinophilic Disorders	N/A
Active, not recruiting	`NCT03678545` - Dupilumab in Eosinophilic Gastritis	Phase 2
Terminated	`NCT01814059` - Sirolimus for Eosinophil-Associated Gastrointestinal Disorders	Phase 1
Active, not recruiting	`NCT05214768` - A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis	Phase 3
Recruiting	`NCT01793168` - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Completed	`NCT03496571` - A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis	Phase 2
Recruiting	`NCT02523118` - OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages
Completed	`NCT05251909` - Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)	Phase 3
Completed	`NCT05439772` - Examining the Effect of Ondansetron on Bowel Prep Success	Phase 4
Completed	`NCT00266565` - Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome	Phase 1/Phase 2
Recruiting	`NCT05199532` - Eosinophilic Gastrointestinal Disorders Registry
Terminated	`NCT01212016` - Immunopathogenesis of Food Allergy and Eosinophilic Gastrointestinal Disorders	N/A
Completed	`NCT02897271` - Characteristics of Eosinophilic Gastritis, Enteritis, and Colitis in a Multi-Site Cohort